Ilia Y. Shilkrot

Ilia Y. Shilkrot

Auto-generated profile, based on publicly available information

Ilia Y. Shilkrot

National Association of Non-Governmental Medical Organizations

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2021 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Open access
PDF file
EAEkaterina Alexeeva
Ekaterina Alexeeva
RTRustem F. Tepaev
Rustem F. Tepaev
ISIlia Y. Shilkrot
Ilia Y. Shilkrot
TDTatyana M. Dvoryakovskaya
Tatyana M. Dvoryakovskaya
ASAleksander G. Surkov
Aleksander G. Surkov
ДМДворяковская Татьяна Маратовна
Дворяковская Татьяна Маратовна
In most cases, COVID-19 has a favorable outcome. However, the risk of developing critical forms of the disease, including secondary hemophagocytic lymphohistiocytosis HLH (cytokine storm syndrome), remains high. This dictates the interest in studying pathogenetic mechanisms, features of the clinical picture, laboratory and instrumental criteria for covid-19 disease. The article analyzes the causes of acute respiratory distress syndrome and multiple organ failure as manifestations of HLH. The necessity of monitoring signs of hyperinflammation (ferritin, C-reactive protein, etc., biomarkers of inflammation) and activation of thrombosis is substantiated, in order to make timely decisions about the beginning of pathogenetic therapy. However, there are limitations for routine testing of the level of Pro-inflammatory cytokines. Information about the diagnostic criteria of HLH is summarized, and the expediency of these criteria for establishing secondary HLH, which has complicated the course of COVID-19, is emphasized.

1 January 2022 in Voprosy praktičeskoj pediatrii
Verified
Journal Article
Closed access
TKT.YU. Kriulina
T.YU. Kriulina
EAEkaterina Alexeeva
Ekaterina Alexeeva
ISI.YU. Shilkrot
I.YU. Shilkrot
TDT.M. Dvoryakovskaya
T.M. Dvoryakovskaya
ASA.G.SUrkov Surkov
A.G.SUrkov Surkov
The incidence of rheumatic diseases has been constantly growing during the last 20 years, which necessitates regular assessment of the healthcare quality for these patients and identification of the most significant problems and ways to address them. Juvenile idiopathic arthritis (JIA) is one of the most frequent disabling rheumatic diseases in children. The incidence and prevalence of JIA allow us to use this disorder to evaluate the organization of rheumatology care in general in terms of its accessibility and quality, as well as measures to improve it. This article reviews JIA epidemiology, characteristics and problems of healthcare organization for children with rheumatic diseases in the Russian Federation and other countries. Key words: healthcare organization, rheumatic diseases, health care, juvenile idiopathic arthritis

1 January 2023 in Voprosy praktičeskoj pediatrii
Verified
Journal Article
Closed access
TKT.Yu. Kriulina
T.Yu. Kriulina
TDT.M. Dvoryakovskaya
T.M. Dvoryakovskaya
ASA.G. Surkov
A.G. Surkov
DSD.S. Shubina
D.S. Shubina
ABA.V. Bairashevskaуa
A.V. Bairashevskaуa
MCMoscow Vademecum Analytical Center
Moscow Vademecum Analytical Center

1 January 2022 in Voprosy praktičeskoj pediatrii
Verified
Journal Article
Closed access
IKIvan Kriulin
Ivan Kriulin
EAEkaterina Alexeeva
Ekaterina Alexeeva
ISI.Yu. Shilkrot
I.Yu. Shilkrot
TDT.M. Dvoryakovskaya
T.M. Dvoryakovskaya
Secondary hemophagocytic syndrome (SHS) is a life-threatening complication of systemic juvenile idiopathic arthritis (SJIA, syn.: systemic-onset juvenile idiopathic arthritis). Timely treatment of SHS can improve outcomes and reduce mortality rates. There has been little evidence worldwide on the effectiveness of therapy for SHS in patients with SJIA, including the use of genetically engineered biopharmaceutical drugs (GEBDs). Objective. To evaluate the efficacy of different treatment regimens for SHS in patients with SJIA. Patients and methods. This study included 100 patients with SJIA complicated by SHS who were examined and treated at the rheumatology department of the National Medical Research Center for Children’s Health (Moscow) from August 2010 to May 2021. All patients met the criteria for SJIA and SHS diagnosis. The efficacy of different therapy regimens for SHS was assessed according to treatment response criteria and achievement of the clinically inactive status of SHS. The Kaplan-Meier survival analysis was used to investigate the proportion and duration of the period prior to SHS recurrence (relapse-free interval) after the end of therapy, including the use of GEBDs for the treatment of SJIA. The proportion of relapse-free survival cases and the duration of relapse-free interval were assessed within 36 months in 79 of 100 patients (89/114 (78%) SHS cases). Results. Medical records of 100 patients with 114 cases of SHS were retrospectively studied. In 84/114 (73%) cases, SHS developed in patients not receiving GEBDs (“biologically naïve”), and in 30/114 (26%) cases, SHS developed against the background of GEBD therapy (“biologically non-naïve”). Combination therapy, which included intravenous (dexamethasone 17.9 [10; 20] mg/m2/day or methylprednisolone 12.1 [5; 20] mg/kg/day) and oral (prednisolone 0.9 [0.5; 2] mg/kg/day) glucocorticosteroids (GCs), as well as cyclosporine (CsA) at a dose of 4.5 [2; 7] mg/kg/day and normal human immunoglobulin (syn. intravenous immunoglobulin; IVIG) at a dose of 1.5 [0.3; 2] g/kg. In 24/114 (21%) cases, GEBDs were prescribed for the treatment of SHS: in 11 (10%) – tocilizumab, in 8 (7%) – canakinumab, and in 5 (4%) – rituximab. Hemophagocytic syndrome resolved in 111/114 (97%) cases, lethal outcome was registered in 3/114 (3%) cases. Conclusion. Response to treatment and inactive SHS status achievement in the shortest possible time were recorded when using a treatment regimen that included intravenous and oral administration of GCs, as well as CsA and IVIG, regardless of the background use of GEBDs for the treatment of SJIA. In “biologically naïve” patients, response to treatment developed faster, and the proportion and duration of relapse-free interval were significantly greater than in “biologically non-naïve” patients. Key words: secondary hemophagocytic syndrome, systemic juvenile idiopathic arthritis, treatment, genetically engineered biopharmaceutical drugs

1 January 2024 in Voprosy praktičeskoj pediatrii
Verified
Journal Article
Closed access
MBM.S. Botova
M.S. Botova
TDT.M. Dvoryakovskaya
T.M. Dvoryakovskaya
TKT.YU. Kriulina
T.YU. Kriulina
EAEkaterina Alexeeva
Ekaterina Alexeeva
ISI.YU. Shilkrot
I.YU. Shilkrot
Juvenile arthritis with systemic onset (syn: systemic juvenile idiopathic arthritis; SJIA) is the most complex in pathogenesis, severe in course and unfavorable in prognosis variant of juvenile arthritis. The course of SJIA is characterized by the development of severe life-threatening complications, which in the future may lead to the progression of functional and multiple organ failure, delayed physical development and disability of the patient, therefore it is very important to diagnose this disease at an early stage, for which children with suspicion of SJIA must be examined in accordance with the Procedure for providing medical care for children in the profile "Rheumatology" in rheumatology departments of multidisciplinary hospitals, where it is possible to perform the entire complex of diagnostic measures, these are indicated in the clinical recommendations, since at the stage of diagnosis it is very important to exclude diseases appearing in the guise of SJIA, including infectious diseases, These are indicated in the clinical recommendations, because at the stage of diagnosis it is very important to exclude diseases appearing under the guise of SJIA, including infectious, oncologic, oncohematologic, lymphoproliferative, inflammatory bowel, autoinflammatory syndromes and other rheumatic diseases. Federal districts (FD) of the Russian Federation (RF) differ significantly in demographic, climatic, natural-geographical, sociocultural parameters, which cannot but determine differences in the processes of providing medical care to children in the profile of rheumatology. The analysis of these processes is a necessary condition for improving the quality of early diagnosis of juvenile arthritis in pediatric patients. Objective. To carry out a comparative assessment of compliance with clinical recommendations of the scope of examination performed in the Russian Federation at the stage of primary diagnosis of juvenile arthritis with systemic onset, according to the Federal Register of the Ministry of Health of the Russian Federation. Patients and Methods. A retrospective study of discharge records of 927 patients diagnosed with SJIA, receiving genetically engineered biological drugs, included in the Federal Register of persons with hemophilia, cystic fibrosis, pituitary nanism, Gaucher disease, malignant neoplasms of lymphoid, hematopoietic and related tissues, multiple sclerosis, hemolytic-uremic syndrome, juvenile arthritis with systemic onset, mucopolysaccharidosis types I, II and VI, persons after organ and/or tissue transplantation (Register). Results. Our study found that there were significant differences between the Russian Federation regions in the volume of investigations performed at the stage of diagnosis of SJIA and their compliance with clinical recommendations. In all regions of the Russian Federation we found a reliable dynamics of improvement in the quality of examination associated with the improvement of the regulatory and legal framework for the organization of medical care for children in the profile of rheumatology. Conclusion. Our study confirms the need for continuous monitoring of the work of pediatric rheumatology service of the FD, which will optimize the algorithms of early diagnosis of SJIA and other rheumatic diseases in children in order to timely start treatment, including on the basis of the introduction and modernization of digital health technologies, in particular, the system of electronic registers. Key words: Federal Register, juvenile arthritis with systemic onset, diagnosis, federal district, clinical recommendations

1 January 2022 in Voprosy praktičeskoj pediatrii
Verified
Journal Article
Closed access
IKIvan Kriulin
Ivan Kriulin
EAEkaterina Alexeeva
Ekaterina Alexeeva
ISI.YU. Shilkrot
I.YU. Shilkrot
TDT.M. Dvoryakovskaya
T.M. Dvoryakovskaya
Background. Secondary hemophagocytic lymphohistiocytosis (sHLH) is a potentially fatal complication of systemic juvenile idiopathic arthritis (sJIA) characterized by hyperinflammation and a variety of clinical and laboratory manifestations. This condition is also referred to as macrophage activation syndrome (MAS) in patients with rheumatic diseases, including those with sJIA. In this article, we use the term sHLH. Approximately 40% of sHLH cases are asymptomatic, especially in patients who receive biologicals. Thus, the development of a prognostic model and identification of early sHLH markers in sJIA patients will enable timely initiation of anti-inflammatory and immunosuppressive therapy. Objective. To develop a prognostic model and identify early sHLH markers in sJIA patients. Methods. This study included 100 sJIA patients who were examined and treated in the Department of Rheumatology, National Medical Research Center for Children's Health between August 2010 and May 2021. A total of 114 sHLH episodes were registered among study participants. We analyzed medication history, as well as clinical and laboratory parameters reflecting the activity of sHLH and sJIA as potential early markers of sHLH. Multivariate logistic regression analysis was used to assess the predictive value of these markers for sHLH development. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for each factor to evaluate its significance. Receiver operating characteristic (ROC) curves were constructed to assess the sensitivity and specificity of the model. Results. We analyzed a number of factors as potential early sHLH markers, including medication history (treatment with oral or injectable glucocorticoids (GCs) before sHLH, immunosuppressants (methotrexate, cyclosporine, or leflunomide), and biologicals (tocilizumab, canakinumab, adalimumab, etanercept)), clinical signs (fever, rash, hepatomegaly, splenomegaly, lymphadenopathy, myalgia, hemorrhagic syndrome, central nervous system (CNS) lesions, kidney lesions, lung lesions, heart lesions), and laboratory parameters (hemoglobin, absolute count of red blood cells (RBCs), white blood cells (WBCs), neutrophils, lymphocytes, and platelets, erythrocyte sedimentation rate (ESR), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), lactate dehydrogenase (LDH), creatinine, blood urea, c-reactive protein (CRP), ferritin, triglycerides, procalcitonin (PCT), total protein, albumin, blood electrolytes (sodium, potassium, chlorides, iron), coagulation parameters (Quick prothrombin, thrombin time, prothrombin time, international normalized ratio (INR), partial thromboplastin time (APTT), D-dimer, fibrinogen, fibrin monomer, von Willebrand factor, protein S, and protein C). Our prognostic model demonstrated that the following variables were significant predictors of sHLH in sJIA patients: lymphadenopathy, red blood cell count <4.34 × 106 cells/mL, platelets <208 × 103 cells/mL, serum chlorides 412 Units/L. The specificity of the model was 98.0%; the overall accuracy was 95.6%. The area under the ROC-curve (AUC) was 0.954 ± 0.027 (95% CI 0.902–1.000; р < 0.001). Conclusion. The most reliable prognostic markers of sHLH in sJIA patients are undoubtedly heterozygous mutations in the genes of primary (familial) hemophagocytic lymphohistiocytosis. In addition to that, lymphadenopathy, decreased RBC and platelet count, decreased serum level of chloride, and elevated serum LDH in sJIA patients can be interpreted as early sHLH markers and, therefore, considered as an indication to enhance anti-inflammatory and immunosuppressive therapy. Key words: secondary hemophagocytic lymphohistiocytosis, systemic juvenile idiopathic arthritis, early markers, prognostic model